会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
    • 受体酪氨酸激酶信号通路分析诊断和治疗
    • US07402399B2
    • 2008-07-22
    • US10963855
    • 2004-10-13
    • Ali MukherjeeiMengxiang TangHarprit S. PannuPo-Ying Chan-HuiSharat Singh
    • Ali MukherjeeiMengxiang TangHarprit S. PannuPo-Ying Chan-HuiSharat Singh
    • G01N33/53G01N33/533
    • G01N33/74G01N33/5041G01N33/57492G01N33/6893G01N2333/485
    • The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.
    • 本发明提供了通过测量受体二聚化和RTK途径特征的蛋白质 - 蛋白复合物或活化的效应蛋白的相对量来确定细胞样品或患者样品中受体酪氨酸激酶(RTK)途径的激活状态的方法。 本发明还提供了使用这种状态信息来选择对途径特异性药物有反应的患者的方法,更具体地,涉及用于测量ErbB受体和受体复合物的方法,并使用这些信息来选择对ErbB途径特异性药物有反应的患者。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物组来实现,所述可释放分子标签对于在RTK活化中形成的一种或多种复合物的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。